Cargando…

CRISPR-Cas9-based target validation for p53-reactivating model compounds

Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wanzel, Michael, Vischedyk, Jonas B, Gittler, Miriam P, Gremke, Niklas, Seiz, Julia R, Hefter, Mirjam, Noack, Magdalena, Savai, Rajkumar, Mernberger, Marco, Charles, Joël P, Schneikert, Jean, Bretz, Anne Catherine, Nist, Andrea, Stiewe, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910870/ https://www.ncbi.nlm.nih.gov/pubmed/26595461 http://dx.doi.org/10.1038/nchembio.1965

Ejemplares similares

ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma
por: Bretz, Anne Catherine, et al.
Publicado: (2016)

Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases
por: Charles, Joël P., et al.
Publicado: (2014)

Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy
por: Klimovich, Boris, et al.
Publicado: (2019)

Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
por: Timofeev, Oleg, et al.
Publicado: (2019)

Robustness of the Autophagy Pathway to Somatic Copy Number Losses
por: Polo, Pierfrancesco, et al.
Publicado: (2022)

Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase
por: Merle, Nastasja, et al.
Publicado: (2022)

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Gremke, Niklas, et al.
Publicado: (2020)

p53 partial loss-of-function mutations sensitize to chemotherapy
por: Klimovich, Boris, et al.
Publicado: (2021)

Galectin-3 interacts with components of the nuclear ribonucleoprotein complex
por: Fritsch, Katharina, et al.
Publicado: (2016)

Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
por: Mansouri, Siavash, et al.
Publicado: (2022)

Characterization of the p53 Cistrome – DNA Binding Cooperativity Dissects p53's Tumor Suppressor Functions
por: Schlereth, Katharina, et al.
Publicado: (2013)

Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors
por: Gebauer, Leonie, et al.
Publicado: (2021)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
por: Pavlakis, Evangelos, et al.
Publicado: (2023)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity
por: Sauer, Markus, et al.
Publicado: (2008)

A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use
por: Jiang, Long, et al.
Publicado: (2022)

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
por: Kadosh, Eliran, et al.
Publicado: (2020)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

MGA, L3MBTL2 and E2F6 determine genomic binding of the non-canonical Polycomb repressive complex PRC1.6
por: Stielow, Bastian, et al.
Publicado: (2018)

Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance
por: Bowden, Anne Ramsay, et al.
Publicado: (2020)

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma
por: Banat, G-Andre, et al.
Publicado: (2015)

Zinc Finger Independent Genome-Wide Binding of Sp2 Potentiates Recruitment of Histone-Fold Protein Nf-y Distinguishing It from Sp1 and Sp3
por: Völkel, Sara, et al.
Publicado: (2015)

Protocols for marker-free gene knock-out and knock-down in Kluyveromyces marxianus using CRISPR/Cas9
por: Rajkumar, Arun S, et al.
Publicado: (2021)

CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Jiang, Long, et al.
Publicado: (2022)

Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy
por: Timofeev, Oleg, et al.
Publicado: (2021)

Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

C1q/TNF-Related Protein 3 (CTRP-3) Deficiency of Adipocytes Affects White Adipose Tissue Mass but Not Systemic CTRP-3 Concentrations
por: Schmid, Andreas, et al.
Publicado: (2021)

Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9
por: Cullot, G., et al.
Publicado: (2023)

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA
por: Rehberger, Miriam, et al.
Publicado: (2022)

Bacteriophages suppress CRISPR–Cas immunity using RNA-based anti-CRISPRs
por: Camara-Wilpert, Sarah, et al.
Publicado: (2023)

Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer
por: Sarode, Poonam, et al.
Publicado: (2020)

Cas6 specificity and CRISPR RNA loading in a complex CRISPR-Cas system
por: Sokolowski, Richard D., et al.
Publicado: (2014)

Cas1–Cas2 complex formation mediates spacer acquisition during CRISPR–Cas adaptive immunity
por: Nuñez, James K., et al.
Publicado: (2014)

A Q methodology study on divergent perspectives on CRISPR-Cas9 in the Netherlands
por: Schuijff, Mirjam, et al.
Publicado: (2021)

CRISPR/Cas-based customization of pooled CRISPR libraries
por: Kweon, Jiyeon, et al.
Publicado: (2018)

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
por: Zhang, Fei, et al.
Publicado: (2019)

Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients
por: Bauer, Marcus, et al.
Publicado: (2019)

Special focus CRISPR-Cas
por: Marchfelder, Anita
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tmod29tmfhjj8p2u53slkmrs4a